During the past decade, Hospital Universitario de Salamanca conducted 329 clinical trials. In the 10-year time frame, 329 clinical trials started and 95 clinical trials were completed, i.e. on average, 28.9% percent of trials that started reached the finish line to date. In the past 5 years, 174 clinical trials started and 66 clinical trials were completed. i.e. 37.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario de Salamanca" #1 sponsor was "PETHEMA Foundation" with 61 trials, followed by "Celgene" with 51 trials sponsored, "Janssen Research & Development, LLC" with 36 trials sponsored, "Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea" with 15 trials sponsored and "Incyte Corporation" with 15 trials sponsored. Other sponsors include 318 different institutions and companies that sponsored additional 186 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario de Salamanca" #1 collaborator was "Celgene Corporation" with 8 trials as a collaborator, "Bristol-Myers Squibb" with 6 trials as a collaborator, "Instituto de Salud Carlos III" with 6 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 6 trials as a collaborator and "AstraZeneca" with 5 trials as a collaborator. Other collaborators include 225 different institutions and companies that were collaborators in the rest 171 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario de Salamanca" are "Multiple Myeloma" (66 trials), "Myelodysplastic Syndromes" (18 trials), "Acute Myeloid Leukemia" (13 trials), "Acute Lymphoblastic Leukemia" (11 trials) and "Breast Cancer" (11 trials). Many other conditions were trialed in "Hospital Universitario de Salamanca" in a lesser frequency.

Most popular intervention types in "Hospital Universitario de Salamanca" are "Drug" (389 trials), "Other" (38 trials), "Biological" (31 trials), "Device" (27 trials) and "Procedure" (15 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (48 trials), "Dexamethasone" (47 trials), "Lenalidomide" (29 trials), "Bortezomib" (25 trials) and "Daratumumab" (21 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario de Salamanca" are 467 trials for "All" genders, 16 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are 215 active trials in "Hospital Universitario de Salamanca". 4 are not yet recruiting, 125 are recruiting, 83 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 216 completed trials in Hospital Universitario de Salamanca, undefined suspended trials, and 47 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario de Salamanca, 72 "Phase 1" clinical trials were conducted, 172 "Phase 2" clinical trials and 163 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 34 trials, and there were also 19 trials that are defined as “Not Applicable".

Hospital Universitario de Salamanca has several departments that took part in Clinical trials: "Hospital Clinico Universitario de Salamanca; Servicio de Oncologia" - 14 trials